ANTX - AN2 Therapeutics, Inc.

4.8
0.460   9.583%

Share volume: 618,572
Last Updated: 04-27-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$4.34
0.46
0.11%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 20%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
12.15%
1 Month
38.73%
3 Months
303.36%
6 Months
272.09%
1 Year
287.10%
2 Year
102.53%
Key data
Stock price
$4.80
P/E Ratio 
N/A
DAY RANGE
$4.32 - $5.11
EPS 
-$1.20
52 WEEK RANGE
$1.00 - $6.91
52 WEEK CHANGE
$293.44
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
35.941 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
2.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$259,880
AVERAGE 30 VOLUME 
$354,745
Company detail
CEO: Eric Easom
Region: US
Website: an2therapeutics.com
Employees: 20
IPO year: 2022
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AN2 Therapeutics is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Recent news